patient selection in braf-mutant nsclc
Published 7 years ago • 166 plays • Length 5:55Download video MP4
Download video MP3
Similar videos
-
7:36
braf/mek efficacy in braf-mutant nsclc
-
4:16
combination therapy in braf-mutant nsclc
-
1:51
dr. bauman on treatments for patients with braf-mutant nsclc
-
4:59
outcomes with chemotherapy in braf-mutant nsclc
-
6:43
considering targeted agents in braf-mutant nsclc
-
3:43
understanding the braf-mutated population in nsclc
-
9:16
changing treatment paradigm for braf-mutant nsclc
-
6:28
dabrafenib and trametinib in braf-mutated nsclc
-
3:10
targeting braf in nsclc
-
1:26
novel treatment strategies for braf v600e-mutant nsclc
-
5:45
subtypes in nsclc: braf and ret
-
2:56
treating braf v600e-mutant nsclc with dabrafenib and trametinib
-
5:16
treatment of braf-mutant nsclc
-
9:16
changing treatment paradigm for braf-mutant nsclc
-
1:58
unmet needs in braf nsclc
-
7:03
patient selection in melanoma: immunotherapy vs targeted therapy
-
5:44
treatment considerations for braf nsclc
-
0:58
dr. shum on mechanisms of resistance in oncogene-driven nsclc
-
1:25
dr. brahmer on chemoimmunotherapy in patients with nsclc